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Abstract
Hypoxia was identiﬁed as a microenvironmental component of solid tumours over 60 years ago and was immediately recognised as a potential barrier to
therapy through the reliance of radiotherapy on oxygen to elicit maximal cytotoxicity. Over the last two decades both clinical and experimental studies have
markedly enhanced our understanding of how hypoxia inﬂuences cellular behaviour and therapy response. Furthermore, they have conﬁrmed early as-
sumptions that low oxygenation status in tumours is an exploitable target in cancer therapy. Generally such approaches will be more beneﬁcial to patients with
hypoxic tumours, necessitating the use of biomarkers that reﬂect oxygenation status. Tissue biomarkers have shown utility in many studies. Further signiﬁcant
advances have been made in the non-invasive measurement of tumour hypoxia with positron emission tomography, magnetic resonance imaging and other
imaging modalities. Here, we describe the complexities of deﬁning and measuring tumour hypoxia and highlight the therapeutic approaches to combat it.
 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Key words: Hypoxia; hypoxia-activated prodrugs; imaging; oxygen; radiationStatement of Search Strategies Used and
Sources of Information
The PUBMED database was interrogated for relevant
literature. Due to space constraints, topical review articles
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instances.Introduction
The term hypoxia has been extensively used to describe a
state of insufﬁcient oxygen, which can be present in tu-
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http://dx.doi.org/10.1016/j.clon.2014.02.002Central to this review is how oxygen levels are measured in
tumours; the units of oxygen concentration and the rele-
vant conversion factors are shown (Table 2). The normal
level of oxygen (tissue normoxia/physoxia) varies widely
between different organs. This should not be confused with
hypoxia, as even the lower levels are sufﬁcient to support
the tissue in question (Table 3). Hypoxia occurs to some
degree in most solid tumours as a result of several factors,
including the rapid growth rate of cancer cells and the
highly disorganised/inefﬁcient vasculature. Within any
tumour, oxygen levels are extremely heterogeneous and can
include mild hypoxia (2% O2) and severe levels of hypoxia
(<0.1% O2). In addition, due to rapid changes in red cell ﬂux,
periods of cycling hypoxia occur, i.e. exposure to hypoxia
levels followed by re-oxygenation.Tumour Hypoxia and Clinical Relevance
The clinical relevance of tumour hypoxia to patient
prognosis has been shown in several elegant studiesier Ltd. All rights reserved.
Table 3
Examples of physoxia measurements for speciﬁc tissues. See ref-
erences for details of sample number and method of measurement
(recently reviewed in [2])
Tissue pO2 (mmHg) % O2 Reference
Brain 35 4.6 [3]
Lung 42.8 5.6 [4]
Liver 31 4.08 [5]
Kidney 72 9.5 [6]
Muscle 25 3.25 [7]
Bone marrow 54.9 7.14 [8]
Skin 8e35 1.05e4.61 [9]
Intestine 61 8.03 [10]
Table 1
Deﬁnition of terms commonly used to describe oxygen levels in
biology
Normoxia Atmospheric oxygen pressure
(20.9% O2). The pO2 where most
preclinical testing is carried out
Physoxia/physioxia Also known as ‘tissue normoxia’.
The normal oxygen pressure in
speciﬁc tissues/organs
(see Table 3).
Hypoxia Low oxygen levels, indicating that
the tissue/organ has insufﬁcient
oxygen. Associated with the
stabilisation of hypoxia inducible
factor-1 (HIF-1).
Radiobiological
hypoxia
The level of hypoxia where signiﬁcant
resistance to radiation is observed
(<0.13% O2) [1].
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oxygenated/hypoxic tumour cells are more resistant to
existing anticancer treatments, including chemotherapy,
radiotherapy and surgery (Figure 1) [17e19]. Hypoxic cells
have been shown to be resistant to chemotherapy for
several reasons. These include the distance from func-
tional vessels, which makes the delivery and diffusion of
drugs challenging, the low proliferation rates of cells in
hypoxic areas and the selection pressure for the loss of
p53-dependent apoptosis [20]. About 50% of all cancer
patients receive radiotherapy either alone or in combi-
nation with other treatment modalities [21]. The efﬁcacy
of radiotherapy is determined by a number of factors,
including the percentage of cells exposed to radiobiolog-
ical levels of tumour hypoxia (Table 1) [18]. Many ad-
vances have been made in improving radiotherapy
outcome and these can be broadly divided into those that
increase the effect on the tumour and those that protect
the normal tissue [13]. It is well known that the presence
of oxygen at the time of ionising radiation will result in
the production of free radicals that create stable organic
peroxides, resulting in DNA damage, which is less easy to
repair by the cell [1]. The consequence of this is an oxygen
enhancement effect where hypoxic cells can be up to
three times more resistant to radiation than those in
normal oxygen concentrations. In addition, tumour hyp-
oxia also predicts for poor outcome, even if the tumour is
surgically removed, as the biological response to hypoxia
includes increased invasion and metastasis [20].Table 2
Commonly used units for oxygen concentration
Units used to deﬁne pO2 Conversion factors
Millimetre of
mercury (mmHg)
1 mmHg ¼ 0.13% O2, 133.3 Pa
Percentage
oxygen (%)
1% ¼ 7.6 mmHg, 1.013 kPaBiological Responses to Hypoxia
The biological responses to hypoxia are extensive and
well beyond the limits of this review. Some of the key
pathways will be covered in brief.
Hypoxia Inducible Factor-mediated Signalling
The main players in the hypoxia response are a family of
heterodimeric transcription factors named hypoxia induc-
ible factors (HIFs), composed of an oxygen-labile alpha (a)
subunit (HIF1a, HIF2a and HIF3a) and a constitutively
expressed HIF1b subunit [22,23]. In the presence of oxygen,
the HIFa subunits bind to the tumour suppressor protein
von Hippel-Lindau, leading to ubiquitination and protea-
somal degradation [24]. By contrast, when oxygen is
limited, the enzymes that modify HIFa (HIF hydroxylases)
become inactive and HIFa is stabilised and translocates to
the nucleus. Once nuclear, HIFa heterodimerises with HIF-
1b and binds to speciﬁc DNA sequences known as HIF-
response elements. Some of the most well-characterised
target genes include the vascular endothelial growth fac-
tor A, carbonic anhydrase IX (CA-IX), the glucose trans-
porter (GLUT1) and erythropoietin. Other HIF-regulated
genes have roles in glucose metabolism, vasodilation,
apoptosis, autophagy, oxygen sensing, invasiveness and
metastasis [25,26].
Suppression of DNA Repair, Unfolded Protein Response and
DNA Damage Response
There is increasing evidence that in an attempt to adapt
to hypoxic conditions, tumour cells repress cellular pro-
cesses that involve high-energy consumption. Under hyp-
oxic conditions, many essential components of the DNA
repair pathways have been shown to be repressed [27].
Homologous recombination, mismatch repair and non-
homologous end-joining have all been shown to be less
effective under hypoxic conditions, suggesting that a gen-
eral response to hypoxia is repression of DNA repair
[28e30]. The mechanisms of DNA repair gene/protein
repression are varied and include roles for HIF, micro-RNAs
and epigenetic modiﬁcations [30e32]. For example, the
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Fig 2. A simpliﬁed schematic of the hypoxia-induced DNA damage
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correlates with increased levels of methylation of a partic-
ular histone (H3K9me2), which were attributed to
increased levels and activity of the histone methyl-
transferase in hypoxia [33]. Key components of the ho-
mologous recombination pathway, such as RAD51 and
BRCA1, have also been shown to be down-regulated under
hypoxic conditions. The mechanism for RAD51 and BRCA1
down-regulation has been reported to be dependent on the
formation of a repressive E2F4/p130 complex at the E2F site
on the gene promoters, and is independent of both HIF-1a
and cell cycle phase [34]. Importantly, the hypoxia-
mediated repression of DNA repair occurs at a variety of
oxygen tensions and not just in regions of almost anoxia,
indicating that larger proportions of tumours will have
repressed DNA repair pathways.
More severe levels of hypoxia (<0.1% O2) have also been
shown to induce speciﬁc responses not observed in milder
hypoxia. One of the responses includes a reduction in pro-
tein synthesis due to ablation of the mRNA translation
initiation through the unfolded protein response [35,36].
Under severe hypoxia, two responses (a rapid and a delayed
one) affect members of the eukaryotic initiation factors
(eIFs) family, which ablate the mRNA translation initiation
process. While in the rapid response, the eIF2a is inhibited;
in the delayed response, prolonged exposure to severe
hypoxia leads to inactivation of eIF4 (reviewed in [35]). An
additional speciﬁc response observed in severe levels of
hypoxia is the DNA damage response (Figure 2)
[35,36,41e43]. In the absence of oxygen, the activity of
ribonucleotide reductase is compromised, leading to
depletion of dNTP levels and replication stress [44]. The
accumulation of single-stranded DNA at the replication
forks induces ataxia telangiectasia and rad3-related (ATR)-mediated signalling, which includes phosphorylation of
H2AX, CHK1 and p53. In addition to the activation of ATR,
ataxia telangiectasia mutated (ATM)-mediated signalling is
also activated in hypoxia, despite the absence of detectable
DNA damage [45,46].Targeting Hypoxia with Selective Therapies
DNA Damage Response and DNA Repair Inhibitors
Hypoxia is one of the major physiological differences
between a tumour and normal tissue and therefore an
attractive therapeutic target [13]. Given the key roles of ATR
and ATM during hypoxia-induced replication stress and re-
oxygenation, these kinases are regarded as potential
E.M. Hammond et al. / Clinical Oncology 26 (2014) 277e288280therapeutic targets in hypoxic tumour cells (Figure 2).
Disruption of these kinases through depletion or expression
of kinase-dead proteins sensitises tumour cells to hypoxia/
re-oxygenation [42]. Recent studies using potent and spe-
ciﬁc inhibitors of cellular ATR activity, such as VE-821 and
VE-822, showed promise in sensitising a variety of cancer
cells to a range of oxygen concentrations [37,47,48]. In
particular, VE-821 enhanced the effects of radiation, not
only in normoxia, but also in hypoxic conditions [37]. Other
ATR inhibitors include NU6027, which was shown to pro-
mote the genotoxic effects of several DNA-damaging agents,
such as cisplatin, hydroxyurea, radiation and temozolomide
[49]. It will be interesting to establish whether these com-
binations will also be effective under hypoxic conditions.
Targeting CHK1, through gene silencing or chemical inhi-
bition, has been shown to be a promising approach in
enhancing tumour cell sensitivity to hypoxia/re-
oxygenation [50,51]. The CHK1 inhibitor AZD7762,
although shown to have no effect under hypoxic conditions,
signiﬁcantly increases cell death after re-oxygenation and
radiation treatment in several tumour cell lines [52e54].
Additionally, in xenograft models of lung cancer with brain
metastasis, treatment with AZD7762 resulted in a pro-
longed survival in response to radiation [54]. More recently,
ATMwas also shown to be a promising target after hypoxia/
re-oxygenation. The ATM inhibitor KU-55933 induced DNA
damage speciﬁcally under severe hypoxic conditions [46].
Moreover, in 2005, studies by Bryant et al. [55] and
Farmer et al. [56] revealed that cancer cells with BRCA1 and
BRCA2 deﬁciencies were extremely sensitive to poly ADP
ribose polymerase (PARP) inhibitors. The explanation
behind this sensitivity lies in the concept of synthetic
lethality: when two repair pathways A (e.g. homologous
recombination) and B (e.g. non-homologous end-joining)
are abrogated alone, the cell remains viable; however, if
both pathways are inhibited, this leads to cell death [57].
Recently, the novel concept of context synthetic lethality
has emerged, and was shown to occur when one of the
pathways is repressed due to the cellular context (e.g.
hypoxia). In response to hypoxia, critical factors involved in
homologous recombination are repressed, e.g. Rad51 and
BRCA1, and this leads to a deﬁciency in repair and increased
sensitivity to PARP inhibitors [58].
Hypoxia-activated Prodrugs
An elegant approach is to exploit the low levels of oxygen
in hypoxic regions and design compounds that are only
activated by enzymatic reduction in such conditions, the so-
called hypoxia-activated prodrugs. Several of these agents
have been described in the literature, including the well-
established tirapazamine, AQ4N, PR-104A, SN30000, RH-1
and TH-302 [59e62]. However, most of these agents have
been designed to induce DNA damage once activated under
hypoxic conditions. The idea of designing hypoxia-activated
prodrugs that can release an active inhibitor of the DNA
damage response directly to the hypoxic regions is
emerging. Recent proof-of-concept studies include the
CHK1 inhibitor (CH-01) and a DNA-PK inhibitor(BCCA621C), each of which is masked by a bioreductive
group. Under hypoxic conditions, reduction of the bio-
reductive group nitro moiety releases the active CHK1 in-
hibitor CH-01, leading to increased sensitivity of hypoxic
cells [63]. In the case of BCCA621C, it was shown to be
effectively released under hypoxic conditions and sensitise
hypoxic radio-resistant cells [64].Clinical Translation of Hypoxia-selective
Therapies
Of course, a hypoxia-selective therapy is going to be of
greater beneﬁt in patients that have hypoxic tumours. The
critical importance of integrating measures of tumour
hypoxia into therapeutic trials is perhaps best exempliﬁed
by the phase III trial of tirapazamine. Substudies conducted
within phase II trials in head-and-neck cancer had exem-
pliﬁed that patients with more hypoxic tumours (identiﬁed
via positron emission tomography [PET] using [18F]-ﬂuo-
romisonidazole [[18F]FMISO]) were more likely to show
local regional failure after chemoradiotherapy than non-
hypoxic tumours (8/13 versus 1/10). This was countered
by the inclusion of tirapazamine into the treatment regimen
(local regional failure hypoxic tumours 1/19 [65]). In the
phase III trial, tirapazamine did not improve outcome in the
overall patient population [66]. However, no measure of
hypoxia was undertaken, so it was impossible to deﬁne
cohorts whomay have been showing an enhanced response
based on the extent of tumour hypoxia. Additional com-
plexities with the quality assurance of radiotherapy further
marred the tirapazamine trial [67]. However, it is now
generally recognised that hypoxia biomarkers are crucial for
trials of hypoxia-selective therapies.Needle Electrodes and Tissue-based
Biomarkers
Oxygenation in tumours can be directly measured using
needle electrodes, a technique that was invaluable in ﬁrst
proving the associations with hypoxia and treatment
response [67e73]. However, this technique is limited to
accessible tumours and, as the equipment went out of
production, is available in very few centres. Alternative
approaches were therefore needed and there are a number
of potential ways of identifying hypoxia in tumour samples.
Some exploit the reducing nature of the hypoxic microen-
vironment, such as the use of pimonidazole, a nitro-
imidazole that binds to macromolecules in cells under
hypoxic conditions. Pimonidazole can be safely given to
patients and binding ascertained in biopsies using speciﬁc
antibodies [74]. It has been used in trials of hypoxia-
modifying therapies (e.g. accelerated radiotherapy with
carbogen and nicotinamide) and successfully tallies with
patients showing the most marked improvements in
response [75]. Pimonidazole has also proved invaluable in
validating the hypoxic regulation of other potential
endogenous tissue markers of hypoxia. From studies using
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proteins CA-IX and GLUT1 were conﬁrmed as potential
surrogates for hypoxia through their coincidental expres-
sion with pimonidazole binding [76]. With the advent of
array-based technologies, hypoxic signatures have been
developed by identifying genes whose expression clusters
with known hypoxia-regulated genes, including CA-IX.
Such signatures have proven highly prognostic [77,78] and
predictive of response to agents that speciﬁcally radio-
sensitise hypoxic cells (nimorazole [79,80]). Clearly, tissue-
based biomarkers have extensive utility in clinical studies.
However, an obvious issue with these approaches is the
need for a biopsy. Biopsies are challenging or impossible in
some tumour types and repeat measurements would be
restricted. Serological markers, such as osteopontin, have
shown some utility [81] and would enable repeat sampling.
However, in both cases, these methods do not reveal het-
erogeneity in hypoxia across a tumour volume, which may
be of relevance in terms of overall response and may also be
a prerequisite of a therapeutic approach, e.g. if you wanted
to increase the radiotherapy dose speciﬁcally to hypoxic
cells.Non-invasive Imaging of Tumour Hypoxia
Imaging affords a means of evaluating hypoxia across an
entire tumour volume and lends itself well to repeat mea-
surements. The most widely established methods for im-
aging hypoxia are based on PET. Magnetic resonance
imaging (MRI) methods are, in theory, attractive options for
serial imaging of tumour hypoxia, as it is widely available
and avoids imparting ionising radiation to patients. How-
ever, at present, its role is less well established than PET-
based methods. Other methods, including biolumines-
cence and photo-acoustic imaging [82], may play a role in
the future, but remain research techniques at present.Measuring Tumour Hypoxia Using Positron
Emission Tomography Imaging
Ideally, a hypoxia PET tracer should target cellular rather
than vascular pO2 at clinically relevant oxygen concentra-
tions only in viable cells and possess uniform and rapid cell
entry (lipophilic molecule), rapid clearance from normoxic
cells (hydrophilic molecule), yielding a high target-to-
background ratio independent of perfusion and be resis-
tant to non-hypoxia-dependent metabolism [83]. None of
the radiotracers that have been used in clinical studies
(Figure 3) fulﬁl all properties and development of better
radiotracers is still on-going. The radiotracers proposed to
date for PET imaging fall broadly into two categories,
nitroimidazoles and copper-complexed dithiosemicarba-
zone (Cu-ATSM) derivatives [86], both of which are subject
to futile cycling in the presence of oxygen, but enzymati-
cally reduced in hypoxic cells leading to cellular retention.
For nitroimidazoles, the mechanism of retention is via the
formation of radical anions that bind to intracellularmacromolecules, whereas Cu(II)-ATSM undergoes reduc-
tion to Cu(I)-ATSM, which is retained in hypoxic cells.
However, through in situ metabolism, Cu(I) can become
dissociated from ATSM and be washed out from cells, pre-
venting its retention, despite the presence of hypoxia [87].
Nitroimidazoles have been generally labelled with 18F (half-
life of 1.83 h) for PET imaging, whereas Cu-ATSM has been
radiolabelled with four different positron emitters of cop-
per, two very short-lived isotopes (62Cu and 60Cu with half-
lives of 0.16 and 0.40 h, respectively), allowing repeated
administrations but limiting the imaging time to less than
1 h, and two longer lived isotopes (61Cu and 64Cu having
half-lives of 3.3 and 12.7 h, respectively) for delayed mea-
surement, more likely to reﬂect hypoxia rather than
perfusion, but at the expense of a higher radiation dose to
the patient (Table 4) [88].
Selection of Radiotracers
PET tracers are at varying stages of validation and eval-
uation, with [18F]FMISO being the most established and
[18F]FAZA increasingly being used. A comparison of radio-
tracers (Table 4) is hampered by the use of tumour models
and tumour types, with varying degrees of hypoxia and
radiotracer uptake being quantiﬁed using different
methods. For the radiotracers used in clinical studies, vali-
dation in rodents showed tumour uptake above background
level that correlates with pO2 electrode measurements and/
or pimonidazole immunohistochemistry and that is sensi-
tive to changes in oxygen tissue concentration [84,89].
Few direct comparisons have been made between
existing radiotracers. Overall, ﬂuorinated nitroimidazoles
have a low tumour uptake relative to surrounding tissue.
Preclinically [18F]FAZA [90,91], and not [18F]FETNIM [92],
has been shown to be superior to [18F]FMISO, whereas [18F]
HX4 was found to be comparable with [18F]FMISO in clinical
head and neck cancer [93], but the imaging time of both
radiotracers was suboptimal in this study [94,95]. There are
also limited reproducibility data that have been collected
only for [18F]FMISO in head and neck cancer [96,97]. Inter-
tumoural differences in hypoxia selectivity of Cu-ATSM
[98,99] have prevented its widespread acceptance as a
hypoxia PET tracer.
Quantiﬁcation of Tumour Hypoxia
Radiotracer uptake in tumours is heterogeneous in time
and in space (Figure 4). The time window for static imaging
should be selected to decouple radiotracer retention from
perfusion, which differ between tumour types and may
vary in different parts of a tumour. High uptake is assumed
to indicate retention in hypoxic cells, but could also result
from slow clearance from normoxic cells. Conversely, low
uptake is assumed to result from rapid washout from nor-
moxic cells, but may also arise from slow entry into hypoxic
cells, especially those poorly perfused. Tissue uptake will be
further confounded by the presence of radiolabelled me-
tabolites, which can differ between species (Table 4), be-
tween individuals and with treatment. Alternatively,
Fig 3. Molecules radiolabelled for use as positron emission tomography (PET) hypoxia tracers ordered by decreasing lipophilicity with date of
ﬁrst publication (adapted from [84,85]).
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potentially characterise both perfusion and retention and
allow hypoxia perfusion patterns to be identiﬁed [100,101].
Hypoxia in PET images is most often quantiﬁed using the
tumour to background ratio at a given time and requires
estimation of ﬁrst the tumour uptake, which can be done
using the maximum value or an average over a given vol-
ume, and second the background uptake, which can be
taken from a neighbouring muscle, the contralateral side
(brain) or blood (sampled or extracted from a blood pool in
PET image). The hypoxic volume is the volume of the
tumour that is hypoxic and its measurement from PET im-
ages requires selection of an uptake threshold, which de-
pends on the radiotracer, the tumour type and the imaging
time, e.g. tumour to background ratio >1.2e1.4 for [18F]
FMISO [102,103]. The hypoxic fraction is the fraction of the
tumour that is hypoxic and its derivation requires that the
whole tumour volume be delineated in addition to the
estimation of the hypoxic volume and this is typically
extracted from other images, either computed tomography
or [18F] 2-ﬂuoro-2-deoxy-glucose PET [104].Application to Hypoxia-modifying Treatments
PET imaging of hypoxia can be used to identify patients
with hypoxic tumours who could beneﬁt most from addi-
tional treatment, either by prescribing hypoxia-modifying
drugs or by increasing the radiation dose to the tumour
[105]. PET imaging with ﬂuorinated nitroimidazoles is being
integrated into clinical trials of hypoxia-modifyingtreatments. Signiﬁcantly fewer head and neck cancer pa-
tients with hypoxic tumours as measured with [18F]FMISO
had locoregional failure after radiochemotherapy with
tirapazamine compared with those who were not given the
hypoxic cell cytotoxin [65]. Less convincing results were
reported with [18F]FAZA in a similar clinical imaging study
[106], despite promising results in mice bearing a murine
breast cancer xenograft (EMT6) [107]. [18F]EF5 uptake in a
human non-small cell lung cancer xenograft model (H460)
was reduced in rats treated with the hypoxia-activated
prodrug SN30000 alone or with radiotherapy and the
changes correlated with baseline hypoxia levels [108]. The
distribution of hypoxia in the images could also be used to
boost the radiation dose to hypoxic subvolumes of the
tumour (called dose painting), exploiting the conformal and
accurate radiation delivery made possible with the devel-
opment of intensity-modulated radiotherapy and image-
guided radiotherapy. Clinical implementation and evalua-
tion await clariﬁcation in the treatment dose delivery [105].Magnetic Resonance Imaging and
Measurement of Hypoxia
Most MRI studies to evaluate tumour hypoxia to date
have used either dynamic contrast-enhanced MRI (DCE-
MRI) or blood oxygen level-dependent (BOLD) imaging. In
DCE-MRI, a gadolinium-based contrast agent bolus is
injected into a vein and the passage of the contrast agent is
tracked through the tumour microvasculature. The pres-
ence of gadolinium species increases the longitudinal
Table 4
Comparison of radiotracers for uptake in different human tumours, peripheral metabolism and dosimetry
[18F]EF5 [18F]FMISO [18F]FETNIM [18F]FAZA [18F]HX4 Cu-ATSM
Tumour to background ratio (TBRmax) for various cancer (imaging time)
Head/neck 1.5*/1.9 (170e180 min) 2.2/3.0y (240e250 min) 1.1y (90e120 min) 1.8 (150 min) 1.8 (90e99 min) 5.5 [62Cu] (10e12 min)
Lung n/a 2.0/2.7 (120/240 min) 2.0y (120e160 min) 2.3 (150 min) 1.6/2.0 (120/240 min) 2.3 [60Cu]x (30e60 min)
Brainz 1.3* (210 min) 1.6 (150e170 min) n/a 5.3 (150 min) n/a 2.2 [62Cu]x (30e40 min)
Cervix n/a n/a 2.0 (120 min) >1 in 5/15
(60e75 min)
n/a 5.9 [60Cu]/7.3 [64Cu]
(30e60 min)
Colon/rectum n/a >1 in 4/6 (120 min) n/a 1.9 (120e135 min) n/a 2.5 [60Cu] (30e60 min)
Prostate n/a >1.4y (120e160 min) n/a 2.2{ (180 min) n/a n/a
Breast n/a 1.15/1.22 (120/240 min) n/a n/a n/a n/a
Pancreas n/a 2.0 (120e150 min) n/a n/a n/a n/a
Kidneys n/a >1.2y (180 min) n/a n/a n/a n/a
Oesophagus n/a n/a >1.3{ (120 min) n/a n/a n/a
Metabolismk (measurement time)
Mouse 0.37 (120 min) 0.50 (120 min) n/a n/a n/a n/a
Rat 0.80 (120 min) n/a 0.80 (120 min) n/a >0.90 (60 min) n/a
Man 0.95 (120 min) 0.94 (90 min) 0.92 (180 min) >0.90 (70 min) 0.82 (120 min) n/a
Effective dose
(mSv/MBq) 18 13 (total body) 15e19 (2e4 h voiding) n/a 27 3 [62Cu], 11 [60Cu],
29 [61Cu], 36 [64Cu]
HIF, hypoxia inducible factor; EF5, [18F]-2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3,-penta-ﬂuoropropyl)-acetamide; FMISO, [18F]ﬂuoromisonid azole; FETNIM, [18F]ﬂuoroerythronitr
oimidazole; FAZA, [18F]ﬂuoroazomycin-arabinofuranoside; HX4, 3-[18F]ﬂuoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol; Cu-ATSM, [60,61,62,64Cu]
copper(ll)-diacetyl-bis(N4-methylthiosemicarbazone).
* Tumour mean SUV reported instead of maximum SUV.
y Blood as background also reported (FMISO). Blood used as background for FMISO (prostate) and background derived from left ventricle for FMISO (kidneys). Plasma and blood
used as background for FETNIM (head/neck and lung, respectively).
z Different background regions used: cerebellum (FMISO), contralateral side (FAZA, Cu-ATSM), normal brain (EF5). Note that only lipophilic radiotracers cross the bloodebrain
barrier.
x Signiﬁcant difference between responders and non-responders (1.5 versus 3.4 for lung) and signiﬁcant difference between HIF-1a negative and HIF-1a positive (1.2 versus 2.9 for
brain).
{ Uptake in benign prostate used as background region (FAZA) and uptake in spleen used as background region (FETNIM).
k Fraction of intact tracer in plasma.
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Fig 4. Coronal (A) and sagittal (B) plane images showing the het-
erogeneity of [18F]-FAZA uptake into a HCT116 colorectal tumour
xenograft. [18F]-FAZA was administered as an intravenous bolus of
about 10 MBq. Four hours later, mice were anaesthetised and scanned
for 20 min using a Siemens Inveon positron emission tomography/
computed tomography. Images show maximum intensity projections
reconstructed using OSEM3D.
E.M. Hammond et al. / Clinical Oncology 26 (2014) 277e288284relaxation rate (termed R1) of protons, causing signal
change, from which estimates of perfusion can be derived
[109]. Several DCE-MRI studies have related such mea-
surements to genetic readouts of hypoxia [110], oxygen
tension [111] and immunohistochemical measurement of
hypoxic fraction [112,113]. However, the strength of these
relationships is inconsistent. This is explained partially by
the fact that different studies measure slightly different MRI
parameters, all of which have an incomplete and varying
relationship to perfusion. Furthermore, chronic hypoxia and
acute transient variations in oxygen tension are affected not
only by oxygen delivery (perfusion), but also by diverse
factors, including haemoglobin saturation, vascular geom-
etry and consumption (oxidative phosphorylation). There-
fore, DCE-MRI estimates of perfusion are at best indirect
estimates of hypoxia and in some circumstances bare little
relationship to hypoxia at all.
BOLD techniques have been developed to exploit the
differences in magnetic resonance transverse relaxation
(termed R2*) induced by regional differences in deoxygen-
ated haemoglobin levels [114]. BOLD measurements are
typically carried out in combination with gas challenge,
designed to alter the oxy- and deoxygenated haemoglobin
ratio dynamically and therefore help map hypoxia. How-
ever, as BOLD measurements are sensitive to changes in
vessel calibre they are subject to ambiguities in interpre-
tation [115,116]. Although the technique has been carried
out in cancer patients for nearly two decades [117], sub-
stantial artefact is found in some body regions, the extent of
which depends on organ site, the control of visceral motion
and the precise protocol adopted. This method has some
success in mapping chronic hypoxic regions (delineated by
pimonidazole adduct formation) in pelvic tumours such as
prostatic carcinoma [118], but signal changes do not corre-
late well with absolute pO2 levels [116]. Despite some initial
encouraging data, there is little current evidence that either
DCE-MRI or BOLD will provide validated, translationalbiomarkers of hypoxia in the near future. There is, therefore,
a need to develop MRI methods of quantifying hypoxia that
are more closely coupled to tissue chronic low oxygen
tension and acute ﬂuctuations in pO2 and are free from the
technical difﬁculties found with BOLD.
One promising method is oxygen-enhanced MRI (OE-
MRI) using a T1-weighted contrast mechanism. It has long
been recognised that oxygen dissolved in blood and tissue
plasma increases R1 in a similar mechanism to gadolinium
[115,116], but the signal change is very small and so this
contrast mechanism has only been exploited more recently,
enabled by improvements in MRI scanner hardware and
analysis methods. Human studies have shown that signal
changes of up to 20% can be measured reliably in a range of
well-vascularised normal tissues and that the technique is
well tolerated [119]. Preclinical experiments have shown
signiﬁcant increases in tumour R1 in a variety of tumour
models [120,121] that relate to hypoxic fraction and vessel
density [122]. A handful of clinical studies across a range of
solid tumours have shown that this method is translational
[122,123], but further studies are required to determine
whether this or other MRI methods provide useful bio-
markers for monitoring therapy and/or determining clinical
outcome for patients undergoing radiotherapy and
hypoxia-modifying therapy.Conclusion
We have appreciated for many years that tumour hyp-
oxia poses a signiﬁcant problem for effective therapy. This
knowledge has led to the development of strategies to
target tumour hypoxia and equally importantly the pre-
clinical testing of novel therapies in conditions that mimic
the tumour microenvironment. It is clear that in order to
enhance our ability to target hypoxic tumour cells we need
to know where they are and how they respond to therapy.
The advances in application of tissue biomarkers and hyp-
oxia imaging discussed here highlight this real and exciting
possibility.
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